SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Ethereum is a global, open-source platform for decentralized applications. In other words, it is a decentralized blockchain platform that enables developers to build and deploy smart contracts and applications without central authority control. Unlike Bitcoin, which primarily functions as digital currency, Ethereum operates as a programmable global computer where developers can create any type of decentralized service.   The platform hosts over $14 billion in DeFi applications with hundreds of thousands of active users across financial protocols, NFT marketplaces, and gaming platforms. Its transition to Proof of Stake in September 2022 reduced energy consumption by over 99%, addressing environmental concerns while strengthening network security.  The network operates through thousands of independent validator nodes that process transactions and execute smart contracts on the Ethereum Virtual Machine. Smart contracts are self-executing programs written in Solidity that automatically carry out agreements when conditions are met, eliminating intermediaries like banks or brokers.   Validators stake ETH as collateral to propose and validate blocks, earning rewards for honest participation while facing penalties for malicious behavior. The EIP-1559 upgrade introduced a dynamic base fee mechanism that burns ETH with each transaction, creating deflationary pressure during high network activity when more ETH is burned than issued to validators.  Vitalik Buterin proposed Ethereum in 2013, but seven co-founders helped build it, including Gavin Wood who created Solidity and the EVM technical specification, and Joseph Lubin who founded ConsenSys. The project launched in July 2015 after raising over $18 million through crowdfunding, quickly becoming the largest blockchain developer community. Major milestones include the 2020 Beacon Chain launch, the 2021 London hard fork implementing fee burning, and the 2022 Merge to Proof of Stake.   Ether (ETH) serves multiple functions: paying transaction fees (gas), staking to secure the network and earn 3-5% annual yields, serving as collateral in DeFi protocols, and purchasing NFTs and digital assets. The asset is increasingly adopted by traditional institutions, with publicly traded companies adding ETH to corporate treasuries to generate staking yields while maintaining blockchain exposure, and in 2024, the SEC approved spot Ethereum ETFs, allowing traditional investors to gain exposure through conventional brokerage accounts.  Ethereum's roadmap focuses on dramatically increasing transaction capacity to over 100,000 per second, reducing confirmation times, and enhancing decentralization while maintaining security against future threats like quantum computing.

Ethereum

Ethereum is currently locked in a tense battle to flip the 1,800 level into support, with community sentiment sharply divided between bullish hopes for a breakout and bearish skepticism regarding its recent consolidation. Traders are closely monitoring this pivotal price action while debating whether the network's ongoing utility and institutional interest are enough to overcome persistent macroeconomic headwinds.

XRP is a decentralized digital asset and the native token of the XRP Ledger, a Layer 1 blockchain designed for high-performance global payments. Its primary value proposition is offering a fast, cost-effective alternative to traditional banking systems by enabling near-instant cross-border settlements that finalize in three to five seconds. By serving as a neutral bridge asset between different fiat currencies, it helps financial institutions lower liquidity costs and eliminates the need for pre-funded accounts.  The network is unique because it utilizes a federated consensus protocol instead of energy-intensive mining or staking. This system achieves deterministic finality through a Unique Node List of trusted validators who must reach an eighty percent agreement threshold to permanently record transactions. This infrastructure supports a sustained throughput of 1,500 transactions per second and includes a built-in decentralized exchange that allows for the automated trading of any tokenized asset without intermediaries.  The project traces its origins back to 2004 with Ryan Fugger before being co-founded in its modern form by Jed McCaleb and Chris Larsen. The company, now known as Ripple, works with major financial institutions as partners and investors to build global payment solutions. To protect the network from spam, a small amount of XRP is burned during every transaction, and the token is further utilized by institutions as collateral to access traditional markets and manage digital asset infrastructure.  Institutional adoption of the asset reached a major milestone in November 2025 when the SEC approved the first wave of spot XRP ETFs. These products, offered by major issuers including Bitwise, Grayscale, 21Shares, Canary Capital, and Franklin Templeton, are now listed on prominent exchanges like the NYSE Arca, Nasdaq, and Cboe BZX. While Ripple remains a key contributor to the ecosystem, the underlying XRP Ledger continues to operate as an open-source and decentralized network.

Ripple

Ripple's XRP is currently a major focus of community debate, driven by speculation over potential Clarity Act legislation and ongoing institutional adoption trials in Japan. Investors are actively divided between those highlighting Ripple's long-term utility in global payment corridors and others frustrated by stagnant price action and the emergence of competing stablecoin solutions.

MP Materials Corp. engages in the production and marketing of rare earth specialty materials. It operates through the following segments: Materials and Magnetics. The Materials segment focuses on the operation of Mountain Pass, which produces refined rare earth oxides and related products, as well as rare earth concentrate products. The Magnetics segment is involved in the operation of Independence Facility, where the company began production of magnetic precursor products. The company was founded by James Henry Litinsky and Michael Rosenthal in 2017 and is headquartered in Las Vegas, NV.

MP Materials Corporation

MP Materials is trending as investors focus on its critical role in U.S. rare earth supply chain independence, specifically regarding its position as a key domestic producer for magnets and defense infrastructure. Community discussions are heavily driven by the intersection of geopolitical tensions with China, government policy tailwinds, and speculation about potential strategic partnerships or further institutional support.

VS Trust - 2x Long VIX Futures ETF

Volatility Shares 2x Long VIX Futures ETF

UVIX is experiencing significant retail interest as traders bet on a potential volatility spike driven by ongoing geopolitical tensions in the Middle East and concerns over market manipulation. The community remains deeply divided, with many debating the impact of reverse splits and contango decay versus the potential for a sudden, explosive move in volatility.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Trump Media & Technology Group is facing intense scrutiny as investors and community members react to reports regarding presidential health, foreign policy tensions with Iran, and the company's financial performance. Discussions are heavily polarized, with many users debating the impact of recent geopolitical instability on the stock while others focus on broader criticism of the current administration's leadership and corporate governance.

ProShares Trust II - ProShares Ultra VIX Short-Term Futures ETF 1.5x Shares

ProShares Ultra VIX Short-Term Futures ETF

UVXY is currently at the center of intense debate among retail traders who are questioning whether the ETF is being artificially suppressed to prop up broader market indices or if it is simply experiencing expected decay. The community is heavily split, with many traders anticipating a significant volatility spike driven by ongoing geopolitical tensions and looming economic uncertainty, while others caution that the instrument is a structural trap prone to long-term value loss.

Cronos is an institutional-grade, high-performance, EVM-compatible Layer-1 blockchain built on the Cosmos SDK and integrated with the Inter-Blockchain Communication (IBC) protocol, designed as the backbone for open, compliant, and AI-accessible tokenized markets. It supports up to 60,000 transactions per second (TPS), 500ms block times, instant finality, and sub-$0.01 fees via Proof of Authority consensus.

Crypto.com Coin

Investors are closely watching Cronos amid discussions of impending regulatory developments and potential ETF launches, while the community remains divided over the impact of persistent token emissions on price performance. Conversations are also heavily focused on the growth of the native meme coin $MERY.X, which traders are linking to $CRO.X due to its community-led 'rug-proof' narrative and significant exchange holdings.

PENGU is the official coin of Pudgy Penguins.  Pudgy Penguins has become the face of crypto with one of the most influential communities in the industry. From large companies wearing the Penguin, to being featured in ETF commercials, to garnering millions of followers and over 100 billion views, the Pengu has become a cultural icon making PENGU the world’s social currency.  PENGU allows for the ever-expanding Pudgy Penguin fanbase and the hundreds of millions of people outside of crypto that see and share the Pudgy Penguin everyday, to join The Huddle. PENGU is a symbol for community, memes, and good vibes.  Believe in Pengu. Believe in the Prophecy.

Pudgy Penguins

Pudgy Penguins is trending as investors debate the disconnect between its massive real-world retail footprint in major stores and its stagnant market performance. While some community members remain bullish, citing long-term brand utility and potential institutional partnerships, others express significant frustration over consistent selloffs and lack of price appreciation compared to other meme tokens.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bull 3X ETF

Direxion Daily Semiconductor Bull 3X Shares

SOXL is trending as market participants debate whether the recent volatility in semiconductor stocks, driven by memory sector movements and geopolitical tensions, presents a buying opportunity or a deeper correction. The community is actively discussing the impact of new IPOs on capital flow and debating the long-term outlook for the AI sector versus the risks of leveraged decay.

IREN Ltd. is a vertically integrated data center business powering the future of Bitcoin, AI and beyond with renewable energy. It is strategically located in renewable-rich, fiber-connected regions across the US and Canada. IREN’s large-scale, grid-connected facilities are purpose-built for the next generation of power-dense computing applications. The company was founded by Daniel Roberts and William Roberts on November 6, 2018, and is headquartered in Sydney, Australia.

IREN Ltd.

IREN Limited

IREN is facing intense selling pressure and high short interest, with investors increasingly frustrated by the lack of major deal announcements and management compensation concerns. While long-term bulls remain focused on the company's energy infrastructure and data center expansion as critical components of the AI buildout, the stock is currently struggling with technical support levels and ongoing dilution fears.

statis crypto Watchlist

Bitcoin

Solana

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$ABBV $SLS @HboFam

I see you’re in damage control mode now that I caught you in a material misstatement (whether negligent or intentional). Instead of admitting your mistake, you double down on it.

It is beyond dispute that the manufacturer halted  the efficacy portion of VIALE-M for slow accrual. That is clearly and unmistakably documented in the medical literature.  

Clearly, that reflects very poorly on these BAT drugs and is quite harmful for the bears’ theory that BAT is indeed the reason why the patients in Regal are living so long - a theory I have always disputed.  I strongly believe that reason is GPS.

I’ve always maintained the super BAT argument is ludicrous, and that what happened in VIALE-M is supportive of that. 

Obviously if Ven/Aza were such a big success somehow the manufacturer would’ve made it right and would’ve come out with the efficacy branch of VIALE-M. 

But I also don’t want to misstate the reasons that are in the medical literature as to why the efficacy portion of VIALE-M was halted (the safety portion was completed with finding published earlier this year).

If that study’s IDMC halted it for futility that’s what it would say in the literature. The record doesn’t reflect that. 

So I will never overstate the record and misrepresent the medical literature to people here. 

Let investors make their own conclusions based on what the record actually states. 

I can certainly give them my opinion, which is that the lead BAT arm drugs, Ven and Aza, do not work for AML remission maintenance, which have I said repeatedly. 

But I’m not going to misrepresent the reason for the discontinuance of the effficacy branch of VIALE-M just because I have a $1 million investment in this stock and therefore feel the need to misrepresent and potentially commit securities fraud to enrich myself. No one should.

I’ll leave that to others who might want a date with the SEC, FBI and in federal court. I prefer to have a clear conscience and sleep at night.

Bottom line - the halting of the efficacy branch of VIALE-M is bullish for the GPS arm in Regal.  

The stated reason was slow patient accrual - not futility.  The IDMC made no such determination in VIALE-M.  

And I absolutely believe if those drugs (Ven/Aza) were effective in maintaining remission in AML, the manufacturer would have solved the issue of slow patient accrual, but chose not to.

Jay Glenn

SoYeon

Noname Nonamer

Longnstrongdong

Stephen

$SLS since you don’t have a full understanding 
 
what is slow accrual, and you’re a fool if you don’t realize abbv is attempting to save face, mitigate the implications 
 
Dr’s weren’t enrolling Because azaven is toxic 
 
$ABBV lost $500M conducting this failed aml cr 1 maintenance trial 
 
quit pretending you are an authority, when you’re obviously not 
 
you don’t even know what stopping for efficacy is

StockTwits Web

SELLAS Life Sciences Group Inc

Abbvie Inc

Hbo Fam

StockTwits for iOS



I see you’re in damage control mode now that I caught you in a material misstatement (whether negligent or intentional). Instead of admitting your mistake, you double down on it.

It is beyond dispute that the manufacturer halted  the efficacy portion of VIALE-M for slow accrual. That is clearly and unmistakably documented in the medical literature.  

Clearly, that reflects very poorly on these BAT drugs and is quite harmful for the bears’ theory that BAT is indeed the reason why the patients in Regal are living so long - a theory I have always disputed.  I strongly believe that reason is GPS.

I’ve always maintained the super BAT argument is ludicrous, and that what happened in VIALE-M is supportive of that. 

Obviously if Ven/Aza were such a big success somehow the manufacturer would’ve made it right and would’ve come out with the efficacy branch of VIALE-M. 

But I also don’t want to misstate the reasons that are in the medical literature as to why the efficacy portion of VIALE-M was halted (the safety portion was completed with finding published earlier this year).

If that study’s IDMC halted it for futility that’s what it would say in the literature. The record doesn’t reflect that. 

So I will never overstate the record and misrepresent the medical literature to people here. 

Let investors make their own conclusions based on what the record actually states. 

I can certainly give them my opinion, which is that the lead BAT arm drugs, Ven and Aza, do not work for AML remission maintenance, which have I said repeatedly. 

But I’m not going to misrepresent the reason for the discontinuance of the effficacy branch of VIALE-M just because I have a $1 million investment in this stock and therefore feel the need to misrepresent and potentially commit securities fraud to enrich myself. No one should.

I’ll leave that to others who might want a date with the SEC, FBI and in federal court. I prefer to have a clear conscience and sleep at night.

Bottom line - the halting of the efficacy branch of VIALE-M is bullish for the GPS arm in Regal.  

The stated reason was slow patient accrual - not futility.  The IDMC made no such determination in VIALE-M.  

And I absolutely believe if those drugs (Ven/Aza) were effective in maintaining remission in AML, the manufacturer would have solved the issue of slow patient accrual, but chose not to.

10xorbust

@10xorbust @HboFam   Hey 10X, the HBOFam guy is just one of @55X_ROI_Q1_2026&#39;s alternate accounts.  The guy is a complete psychopath.

   Hey 10X, the HBOFam guy is just one of 

's alternate accounts.  The guy is a complete psychopath.

@FlockOfSeagulls @HboFam @55X_ROI_Q1_2026 I see.  No idea who it is.  I made my point and correct statement with which I did not agree.

John c

 I see.  No idea who it is.  I made my point and correct statement with which I did not agree.

@10xorbust hey any thoughts on this study, relapse free survival time seems pretty high, obviously CR1 though like viale-m. 

https://pubmed.ncbi.nlm.nih.gov/38548404/

University of Texas MD Anderson Cancer Center, MDS/AML Moon Shot, Genentech.

PubMed

Reduced dose azacitidine plus venetoclax as maintenance therapy in acute myeloid leukaemia following intensive or low-intensity induction: a single-centre, single-arm, phase 2 trial - PubMed

 hey any thoughts on this study, relapse free survival time seems pretty high, obviously CR1 though like viale-m. 



Paul

@puzzled222 am very familiar with the Bazinet study as it’s one of the bears repeatedly bring up. ￼ I believe I posted about this not long ago in one of my top three studies that bears like to bring up.

It has absolutely no application to Regal. Let me explain why.

 1.  The Bazinet patients were all in CR1.  In contrast, Regal patients are post-relapse CR2/CRp2.  CR1 is a much early stage of AML with a much better prognosis and much longer median survival time.  ￼ Stated differently , the CR2 patients are sicker and closer to death.
￼
2. Bazinet had no control arm.  Regal does.

3.  Bazinet enrolled only 35 patients at one center.  Regal enrolled 126 patients at leading cancer centers across the globe.

4.  Bazinet closed early for slow accrual.  Regal will go to the end.

5.  Bazinet’s primary endpoint was relapse free survival.  Regal’s is overall survival.

6.  Bazinet’s cohort contained many favorable risk, MRD negative and venetoclax sensitive patients. 

7.  Transplantation censoring affected the RFS analysis in Bazinet.

8.  Bazinet was a Phase 2 small trial in one center.  Regal is a much larger phase 3 trial in many centers.

Bottom line is that the BAT drugs in this very small study are poised to return much higher statistics than regal. This was a little phase 2 study of patients in one center only with no co from arm were are a lot healthier and much earlier on in their disease process and where they designed the study protocol to exclude a lot of the potentially sicker patients on top of that.

 am very familiar with the Bazinet study as it’s one of the bears repeatedly bring up. ￼ I believe I posted about this not long ago in one of my top three studies that bears like to bring up.

It has absolutely no application to Regal. Let me explain why.

 1.  The Bazinet patients were all in CR1.  In contrast, Regal patients are post-relapse CR2/CRp2.  CR1 is a much early stage of AML with a much better prognosis and much longer median survival time.  ￼ Stated differently , the CR2 patients are sicker and closer to death.
￼
2. Bazinet had no control arm.  Regal does.

3.  Bazinet enrolled only 35 patients at one center.  Regal enrolled 126 patients at leading cancer centers across the globe.

4.  Bazinet closed early for slow accrual.  Regal will go to the end.

5.  Bazinet’s primary endpoint was relapse free survival.  Regal’s is overall survival.

6.  Bazinet’s cohort contained many favorable risk, MRD negative and venetoclax sensitive patients. 

7.  Transplantation censoring affected the RFS analysis in Bazinet.

8.  Bazinet was a Phase 2 small trial in one center.  Regal is a much larger phase 3 trial in many centers.

Bottom line is that the BAT drugs in this very small study are poised to return much higher statistics than regal. This was a little phase 2 study of patients in one center only with no co from arm were are a lot healthier and much earlier on in their disease process and where they designed the study protocol to exclude a lot of the potentially sicker patients on top of that.